BR122021023230B8 - Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado - Google Patents

Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado

Info

Publication number
BR122021023230B8
BR122021023230B8 BR122021023230A BR122021023230A BR122021023230B8 BR 122021023230 B8 BR122021023230 B8 BR 122021023230B8 BR 122021023230 A BR122021023230 A BR 122021023230A BR 122021023230 A BR122021023230 A BR 122021023230A BR 122021023230 B8 BR122021023230 B8 BR 122021023230B8
Authority
BR
Brazil
Prior art keywords
vaccine
live attenuated
combination
attenuated parvovirus
parvovirus
Prior art date
Application number
BR122021023230A
Other languages
English (en)
Other versions
BR122021023230B1 (pt
Inventor
Norman Spibey
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR122021023230B1 publication Critical patent/BR122021023230B1/pt
Publication of BR122021023230B8 publication Critical patent/BR122021023230B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14341—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a invenção se refere aos parvovírus vivos atenuados, seus usos, vacinas compreendendo tais parvovírus vivos atenuados, bem como métodos para sua produção.
BR122021023230A 2010-07-16 2011-07-18 Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado BR122021023230B8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10169872.8 2010-07-16
EP10169872 2010-07-16
US36568410P 2010-07-19 2010-07-19
US61/365,684 2010-07-19
BR112012030659A BR112012030659B8 (pt) 2010-07-16 2011-07-18 Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas
PCT/EP2011/062203 WO2012007589A1 (en) 2010-07-16 2011-07-18 Live attenuated parvovirus

Publications (2)

Publication Number Publication Date
BR122021023230B1 BR122021023230B1 (pt) 2023-01-17
BR122021023230B8 true BR122021023230B8 (pt) 2023-12-12

Family

ID=42629432

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012030659A BR112012030659B8 (pt) 2010-07-16 2011-07-18 Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas
BR122021023230A BR122021023230B8 (pt) 2010-07-16 2011-07-18 Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012030659A BR112012030659B8 (pt) 2010-07-16 2011-07-18 Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas

Country Status (12)

Country Link
US (1) US9186398B2 (pt)
EP (2) EP3199178B1 (pt)
JP (2) JP6061850B2 (pt)
CN (2) CN102985108A (pt)
BR (2) BR112012030659B8 (pt)
CA (1) CA2802283C (pt)
DK (2) DK2593136T3 (pt)
ES (1) ES2623149T3 (pt)
FR (1) FR21C1022I2 (pt)
NL (1) NL301108I2 (pt)
PT (1) PT2593136T (pt)
WO (1) WO2012007589A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007589A1 (en) * 2010-07-16 2012-01-19 Intervet International B.V. Live attenuated parvovirus
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
JP5980947B2 (ja) * 2012-11-22 2016-08-31 旭化成メディカル株式会社 高感染価のパルボウイルスの生産方法
CA2892221A1 (en) * 2012-12-19 2014-06-26 Intervet International B.V. Canine parvovirus type 2c isolates and methods of use
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
JP6414409B2 (ja) * 2014-07-29 2018-10-31 株式会社微生物化学研究所 弱毒化パルボウイルスおよび弱毒化パルボウイルスを用いたワクチン
CN109735505A (zh) * 2018-12-26 2019-05-10 河南农业大学 一株犬细小病毒毒株及其基因序列的扩增和应用
CN110845582B (zh) * 2019-12-23 2021-07-23 杭州贤至生物科技有限公司 一种猫细小病毒重组蛋白及其单克隆抗体的制备
CA3196668A1 (en) 2020-11-04 2022-05-12 Intervet International B.V. Canine parvovirus
CN114426956B (zh) * 2022-02-08 2023-11-17 辽宁益康生物股份有限公司 猫狂犬病泛白细胞减少症鼻气管炎鼻结膜炎四联灭活疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885585A (en) * 1994-11-08 1999-03-23 Cornell Research Foundation, Inc. Attenuated canine parvovirus vaccine
US5814510A (en) * 1994-11-08 1998-09-29 Cornell Research Foundation, Inc. Attenuated canine parvovirus vaccine
DK2158211T3 (en) * 2007-05-31 2016-12-05 Medigene Ag Mutated structural protein of a parvovirus
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
SG182206A1 (en) 2007-06-14 2012-07-30 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
WO2012007589A1 (en) * 2010-07-16 2012-01-19 Intervet International B.V. Live attenuated parvovirus

Also Published As

Publication number Publication date
JP2017029140A (ja) 2017-02-09
DK3199178T3 (da) 2020-04-14
PT2593136T (pt) 2017-05-03
EP3199178B1 (en) 2020-02-19
NL301108I2 (nl) 2024-01-29
BR122021023230B1 (pt) 2023-01-17
CA2802283A1 (en) 2012-01-19
ES2623149T3 (es) 2017-07-10
BR112012030659B8 (pt) 2022-10-04
BR112012030659B1 (pt) 2021-12-21
EP3199178A1 (en) 2017-08-02
CA2802283C (en) 2018-06-05
BR112012030659A2 (pt) 2017-01-24
FR21C1022I2 (fr) 2024-03-29
CN107254451B (zh) 2021-12-10
FR21C1022I1 (fr) 2021-07-16
JP2013535188A (ja) 2013-09-12
WO2012007589A1 (en) 2012-01-19
BR112012030659A8 (pt) 2021-09-28
CN102985108A (zh) 2013-03-20
JP6298499B2 (ja) 2018-03-20
EP2593136B1 (en) 2017-03-08
CN107254451A (zh) 2017-10-17
US9186398B2 (en) 2015-11-17
EP2593136A1 (en) 2013-05-22
US20130195913A1 (en) 2013-08-01
JP6061850B2 (ja) 2017-01-25
DK2593136T3 (en) 2017-05-08

Similar Documents

Publication Publication Date Title
BR122021023230B8 (pt) Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado
UY35812A (es) ?loci de maíz óptimos?.
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
BR112016015105A2 (pt) Conjugados var2csa-droga
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
MX359769B (es) Metodos para descelularizar huesos.
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
UY34767A (es) Inhibidores cíclicos del enlace éter de dgat1
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
IT1398317B1 (it) Nuovo procedimento per la preparazione del dronedarone.
EA201300513A1 (ru) Волокна для контролируемого разложения
IT1400545B1 (it) Procedimento per la preparazione di tessuto biologico per protesi biologiche.
IT1403244B1 (it) Procedimento per la produzione di lipidi da biomassa.
UY34349A (es) OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
IT1402974B1 (it) Processo per la preparazione del nebivololo.
UY34286A (es) Diagnóstico de vacuna mejorado
CO6470817A2 (es) Cristales de solvato novedosos
MX2012002299A (es) Uso de cetoenoles ciclicos contra bacterias fitopatogenas.
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
BR112014028443A2 (pt) composição estéril.
UY34408A (es) Nuevos moduladores de trpv3

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2715 DE 17/01/2023, QUANTO AO QUADRO REIVINDICATORIO.